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Abstract. A blood test that captures cumulative exposure over time and assesses levels of naturally acquired immunity
(NAI) would provide a critical tool to monitor the impact of interventions to reduce malaria transmission and broaden
our understanding of how NAI develops around the world as a function of age and exposure. This article describes a
collaborative effort in multiple International Centers of Excellence in Malaria Research (ICEMRs) to develop such
tests using malaria-specific antibody responses as biosignatures of transmission and immunity. The focus is on the
use of Plasmodium falciparum and Plasmodium vivax protein microarrays to identify a panel of the most informative
antibody responses in diverse malaria-endemic settings representing an unparalleled spectrum of malaria transmission
and malaria species mixes before and after interventions to reduce malaria transmission.
INTRODUCTION
The ability to accurately and rapidly monitor the effective-
ness of malaria interventions to reduce transmission and the
burden of disease is essential for an effective control pro-
gram. Current methods usually measure the prevalence of
parasitemia in children, and either passive or active case
detection of symptomatic malaria. Although these methods
are useful, they can be resource intensive and imprecise, espe-
cially in areas with low or changing transmission. A blood
test that captures cumulative exposure, recent exposure, and
assesses levels of naturally acquired immunity (NAI) against
malaria would be extremely valuable. This article describes
a collaborative effort in multiple International Centers of
Excellence in Malaria Research (ICEMRs) to develop such
a test using malaria-specific antibody responses as biosigna-
tures of transmission and immunity. The rationale of using
antibodies comes from the observation that antibodies against
specific parasite antigens persist in time and at reasonably
stable concentrations, even when transmission is seasonal.
The antibodies in sera are relatively easy to measure through
experiments using basic techniques such as enzyme-linked
immunosorbent assay or more advanced approaches such as
bead arrays or protein microarrays on a genomic scale.
Human infection with Plasmodium spp. induces potent antibody
responses that increase with subsequent exposure and include
three basic characteristics: 1) circulating immunoglobulin, espe-
cially immunoglobulin G (IgG); 2) plasma cells, predominantly
located in the bone marrow, that produce these antibodies; and
3) memory B cells that can rapidly expand to generate addi-
tional antibody-producing plasma cells, more memory B cells,
and potentially immunoregulatory B cells. These three compo-
nents are often correlated, but sometimes may not be.1,2 For
example, the absence or low levels of serum antibodies may
belie the presence of good memory responses or the reverse.
Immunological memory to malaria as measured by the
presence of serum antibodies to plasmodia blood-stage anti-
gens can persist for years as can the presence of circulating
memory B cells,3–6 even in the absence of malaria exposure.3
As with most infections, antibody levels to plasmodia wane
in the absence of reinfection and increase with reexposure.7
The durability of antibody responses to malaria antigens can
be highly variable. The mechanisms underlying this vari-
ability are unclear,8–10 but are likely related to the way the
antigens are processed and presented by individuals (i.e., the
host genetic component), the type of memory T-cell response
induced, whether the memory B cells and/or plasma cells
are expanded, maintained, or destroyed, and/or whether anti-
bodies are consumed in the process of removing malaria para-
sites.11 These varied kinetics of antibody responses provide a
large and diverse set of potential biosignatures of exposure
and acquired immunity, the ideal characteristics of which will
vary depending on the epidemiologic setting. An ideal anti-
body response to monitor transmission or NAI might be one
that persists several months in moderate-to-low transmission
conditions. By contrast, antibodies with shorter half-life might
be preferable in high-transmission settings (Figure 1).
The strength of cross-ICEMR studies is the ability to use
standardized assays to measure antibody responses in a broad
variety of epidemiological settings ranging from areas with
high transmission to those with low or unstable transmission.
Moreover, many of the ICEMR sites are undergoing malaria
control measures such that the effects of the reduction in
malaria transmission on infection and disease can be evalu-
ated. This study describes the development of a Plasmodium
falciparum (Pf )/Plasmodium vivax (Pv) protein microarray
designed to measure biosignatures of transmission and acquired
immunity across a large number of malaria-endemic sites.
Protein microarrays of the format used in the cross-ICEMR
survey have been previously used to measure antibody responses
to malaria antigens in the context of exposure and acquired
immunity.12–18 This study is novel in that a standard platform
is used across many sites that span the breadth of malaria
transmission and comprise areas with exclusively Pf, exclu-
sively Pv and locations where both parasites are transmitted.
METHODS
Study sites. A detailed discussion of the ICEMR study sites
and epidemiology related to these sites are indicated in other
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articles in this volume. An overview of the studies and related
epidemiology and the number of individuals whose sera was
used to probe the arrays is provided in Table 1.
Ethical approvals. Ethical approval was obtained from
all ICEMR centers in the United States and the FWA-
accredited ethical review boards in the respective malaria
endemic areas.
Protein microarray platform. All sequences for this par-
ticular array were derived from a single reference genome
(3D7). This approach allowed the evaluation of a greater
breadth of antigens, but limited evaluation of the effect of
antigenic variation on the antibody response. Separate studies
outside the ICEMR program to evaluate the latter are
ongoing. Microarrays (Antigen Discovery Inc., Irvine, CA)
were printed and probed following previously published
methods.12,19 In brief, proteins were expressed in cell-free
in vitro transcription/translation (IVTT) reactions from T7
promoter plasmids in our existing Pf clone library. Each
protein contains N-terminal poly-His and C-terminal hemag-
glutinin tags for quality control. Serum samples were diluted
1:200 in Protein Array Blocking buffer (GVS Life Sciences,
Sanford, ME) supplemented with 10% Escherichia coli
lysate (Antigen Discovery Inc., Irvine, CA), and incubated
overnight on arrays at 4°C. After incubation with secondary
antibody and wash steps, slides were scanned on a GenePix
4200AL (Molecular Devices, Sunnyvale, CA) and spot inten-
sities quantified using ScanArray Express software (Perkin
Elmer, Waltham, MA).
Analysis of the array data. The mean pixel intensity for
the spot was subtracted by the local background around the
spot and a floor of 100 was set for the data. The IVTT pro-
tein spot intensities were normalized either by dividing by or
subtracting the multiple IVTT control spots (IVTT reactions
lacking plasmid template) that are printed throughout the
chip. Statistical analyses were performed on the base-2 loga-
rithm of the normalized data using the base stats package
in R (www.r-project.org) to calculate two-sided t test and
P values adjusted for false discovery. The fold-over control
(FOC) normalization reduces variation in signals that could
potentially arise between probing operations performed at
different times. FOC normalization provides a relative measure
of the specific antibody binding to the nonspecific antibody
binding to the IVTT controls. Thus, with the normalized,
log2-transformed data, a value of 0.0 means the intensity is
not different from background and a value of 1.0 indicates
a doubling with respect to background. However in some
analyses, straight mean fluorescence indices (MFI) minus
IVTT background were used.
The number of seropositive antigens in different loca-
tions was determined relative to North American controls
using significance analysis of microarray implemented in
the MultiExperiment Viewer microarray software suite from
TM4 (www.tm4.org). In this analysis, only positive serological
responses that were significantly different from the U.S. con-
trols were counted as seropositive.
Upload of array data to PlasmoDB. All data were uploaded
on PlasmoDB (http://plasmodb.org/plasmo/) that provides free
access to information on Plasmodium genomes and individual
genes identified for the ICEMR array.
RESULTS
Development of the Pf500/Pv500 protein array for trans-
ICEMR sampling. To develop a protein array that was most
informative about exposure and immunity as well as cost
effective, we designed an array containing approximately
TABLE 1
Exposure and ages of samples used for arrays
Study site Country
No. of samples
probed
Exposure
category* Parasites Ages (years)
Tororo Uganda 40 High Pf ≥ 18
Jinja Uganda 40 Moderate Pf ≥ 18
Kanungu Uganda 40 Moderate Pf ≥ 18
Mugil Papua New Guinea (PNG) 20 High Pf = Pv ≥ 18
Tak Thailand 153 Moderate Pv > Pf ≥ 18
Santa Emilia Peru 324 Moderate Pv = Pf All ages
Madre de Dios Peru 40 Low Pv ≥ 18 years
Macha Zambia 244 Low Pf All ages
Chikwawa Malawi 33 High Pf ≥ 18
Thyolo Malawi 33 Moderate Pf ≥ 18
Ndirande Malawi 33 Low Pf ≥ 18
Ngella Solomon Islands 164 Low Pv >> Pf All ages
Tierralta/Cordoba Columbia 340 Low Pv All ages
Remansinho Brazil 281 Moderate Pv >> Pf All ages
Senegal 160 Low Pf All ages
*Currently these estimates of exposure are approximate and based on a number of different measures such as parasite incidence and prevalence rates, entomological inoculation rates, and
in a few cases the molecular force of infection, which is the number of new malaria infection per year based on molecular typing of parasites.
FIGURE 1. Preferable characteristics of antibody responses to anti-
gens for biosignatures of exposure and immunity. Under conditions
of moderate-to-low transmission antibody responses last months
may be optimal (solid line). By contrast, antibody responses that
last weeks (dotted line) might be better measure of recent infection
or perhaps exposure under high transmission conditions. Horizontal
dotted line indicates threshold of detection.
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500 antigens from both Pf and Pv (Pf500/Pv500) for the
trans-ICEMR serological survey. Antigens to be included on
this array were down-selected from larger arrays probed with
highly reactive sera representative of different populations
around the globe. Thus for the Pf features, an array of well-
known Pf genes with 4,528 features (Pf4528) was probed with
adult samples from Papua New Guinea (PNG), Kenya, Mali
(N = 20 each), and the United States as a negative control
(N = 10). Kenya and Mali are high-transmission areas with
ostensibly only Pf transmission, while PNG has high trans-
mission of both Pf and Pv and reacts very strongly with
antigens from both species on the protein arrays. For Pv,
Pv444120 was probed with adult samples from PNG, China
(N = 15 each), Peru (N = 22), Thailand (N = 10), and the
United States (N = 10). Seroreactive antigens in each country
were defined as those antigens with an average signal that
was above a cutoff defined as the average plus two standard
deviations of the U.S. control population. From the compiled
list of seroreactive antigens, the top 500 Pf and 500 Pv anti-
gens were selected using hierarchical filtering. Highest pri-
ority was given to antigens seroreactive in all countries tested,
with the remaining positions allocated by descending order
of reactivity across the countries (Figure 2). The features
selected for the Pf500/Pv500 array were deposited in the NCBI
Gene Expression Omnibus database via accession number
GPL18316 (www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=
GPL18316). On the basis of the information from plasmodb.org,
the distribution of Pf life stage of maximum expression rep-
resented on the array were as follows: merozoite 24%, early
ring 22%, late schizogony 14%, early trophozoite 14%, early
schizogony 11%, late trophozoite 8%, late ring 5%, and
null 2%, representing almost exclusively blood-stage anti-
gens.12 Life-stage expression information was not available
for P. vivax proteins.
Relationship between transmission intensity and breadth of
antibody response using samples from the ICEMR surveys.
Figure 3 shows the breadth of response to the array as deter-
mined by the number of features recognized. For this analysis,
seroreactive adults were used regardless of parasitemic status,
with the aim of providing the largest sample sizes. Sera from
several sites were highly reactive. For example, of the 500 Pf
features on the ICEMR array, > 300 were reactive with sera
from PNG (Pacific southwest ICEMR). Adults from Uganda
(Jinja, Kanungu, and Tororo combined), Thailand (Tak Prov-
ince), and Santa Emila in Peru detected similar numbers of
reactive antigens to that observed in PNG. Overall, sera from
sites with higher transmission recognized more antigens in the
array compared with areas with lower transmission.
In areas with little or no Pv transmission (e.g., Uganda,
Malawi, and Zambia), sera recognized many Pv features
suggesting cross-reaction between antigens (see “Species speci-
ficity of assays” below). Similarly in areas with predominantly
or only Pv transmission (Colombia, Brazil, and Thailand), sera
also recognized Pf antigens. Overall sera recognized fewer
Pv than Pf features. This may represent higher parasitemia
levels associated with Pf infections and stronger boosting of
antibody responses to blood-stage antigens.
Species specificity of assays. Intuitively, Plasmodium species-
specific genes may give rise to species-specific antigens. How-
ever, the majority of genes in Pf and Pv are orthologs of
each other, and therefore, it is likely they share epitopes for
antibody recognition. This portends antigenic cross-reactivity
that will complicate the interpretation of antibody recognition
of malaria proteins, especially in areas of the world where
there is coincident exposure to both Pf and Pv. Through
the ICEMR program, it has been possible to assess serology
in essentially mono-exposed populations. Thus, the antibody
profiles in samples from sub-Saharan Uganda, Senegal,
Malawi, and Zambia primarily represent Pf mono-infections,
although a low level of Pv exposure might occur in some
of these populations.21,22 In addition to robust reactivity to
Pf antigens, there was also strong reactivity to a subset of
Pv antigens, which we attribute to antigenic cross-reactivity
(see Figure 3). Reciprocally, certain populations in Peru have
been identified as Pv mono-infections (notably a mining com-
munity in Madre de Dios where there has not been a case
of falciparum malaria for over a decade). Here too there was
cross-reactivity to a subset of Pf antigens. As might be pre-
dicted, many orthologous genes encode cross-reactive antigens
FIGURE 2. Schematic showing down-selection of antigens for Inter-
national Centers of Excellence in Malaria Research (ICEMR) Pf500/
Pv500 protein microarray.
FIGURE 3. Numbers of different seroreactive antigens detected (sig-
nificance analysis of microarrays) by samples from different Inter-
national Centers of Excellence in Malaria Research (ICEMR)
regions revealed by probing against the Pf500/Pv500 protein micro-
array. Table 1 describes the samples tested. PNG = Papua New Guinea;
SE = Santa Emilia; MDD = Madre de Dios; IQT = Iquitos.
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and reciprocally non-orthologous antigens are more abundant
among those that are species specific. However, there were
exceptions as shown in Figure 4. For example, there are
antigens encoded by Pf that have shared orthologs in Pv,
but which were recognized only in Pf infections (Figure 4B).
Similarly, there are Pv antigens that have orthologs in Pf
but which were Pv specific (Figure 4D). Presumably, this
phenomenon reflects the differing biology of Pf and Pv
infections that changes the antigenicity of a given homolog
depending on the infecting species. In this context, “anti-
genicity” may be influenced by any number of properties
of the protein that determine its exposure to the immune
system, such as its abundance, duration of expression, or sta-
bility. Other lead candidates for species-specific antigens
recognized by antibodies are those for which there are no
orthologous antigens between these two species (Figure 4A
and C). Such analyses help to identify lead candidates for
species-specific biosignatures of transmission and immunity
in Pf and Pv co-endemic areas. It should be mentioned that
Plasmodium malariae (Pm) and/or Plasmodium ovale (Po)
are also co-endemic in some ICEMR study sites23,24 that may
also express cross-reactive antigens to Pf and/or Pv.
Identification of antigens most strongly associated with
transmission. To determine which antibody responses are
likely to be most informative in different epidemiologic set-
tings, it is critical to understand the natural variation in
responses across these settings. Shown in Figure 5 is an ini-
tial trans-ICEMR analysis of protein microarray data from
some of the sites sampled as part of the ICMER program
for which biosignatures of exposure will be evaluated. The
figure provides an overall summary of the breadth and vari-
ability of antibody response between different populations
with varying transmission.
Figure 5A is derived from cross-sectional studies of adults
from different ICEMRs and compared with those of the
United States. The slope of the line is proportional to the
breadth and intensity of the antibody profile with respect
to levels of responses in all the populations examined, with
each dot representing a single antigen. The y axis value for
each antigen represents the mean reactivity to that antigen in
FIGURE 4. Trans International Centers of Excellence in Malaria Research (ICEMR) seroreactivity patterns of candidate Plasmodium
falciparum- and Plasmodium vivax-specific antigens. Shown are Pf500/Pv500 protein microarray data of representative parasite-specific
antigens, identified by comparing P. falciparum and P. vivax mono-infections from Uganda and Peru, respectively (see text for details).
P. falciparum antigens, without (A) and with (B) orthologs in P. vivax. Plasmodium vivax antigens, without (C) and with (D) orthologs in
P. falciparum. Reactivity for each antigen is expressed as mean fluorescence intensity ±standard error of the mean (SEM). Different
ICEMRs are listed at the foot of the figure (see Figure 2 for details) and have been sorted from left to right by the mean fluorescence
intensity (MFI) for PF10_0356-e2s2 (LSA1). These sites resolved into three distinct groups as indicated by the dashed lines: predominantly
P. falciparum (left), predominantly P. vivax (right), and both species (middle).
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FIGURE 5. (A) A trans International Centers of Excellence in Malaria Research (trans-ICEMR) survey of seroreactivity of adults (≥ 18 years;
Table 1) in several malaria endemic regions (PNG, Solomon Islands, Thailand, Senegal, Zambia, and the United States). In each ICEMR site,
average signals of adults in each ICEMR site (y axis) were plotted against the average for all ICEMR sites (x axis). Each point represents
the mean fold over control (FOC) signal intensity for all individuals examined in the particular population to a particular antigen. The number
of individuals examined in each area is shown in Table 1. PNG = Papua New Guinea; US = United States. The slope of the line is proportional
to the overall intensity of response to both Pf and Pv protein arrays. (B) Shows similar data, but the level of reactivity of multiple locations within
four different ICEMR sites, two with predominantly Pf (sub-Saharan Africa) and two predominantly Pv (South America).
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the particular population and the x axis the average reactivity
for all sites. Note that the United States has the lowest slope
and provides a useful baseline.
It should be emphasized that an analysis of this kind is
highly dependent on the sampled populations, and it is pos-
sible to find a range of seroreactivity within the same country,
particularly in low-transmission areas, which may be the reason
why the slopes of the lines are low (i.e., most antigens have
low reactivity) for Senegal and Zambia. For example, Figure 5B
shows individual ICEMR sites with multiple locations within
each site, each with differing transmission intensities. In this
figure, the antigens represented have been selected to rep-
resent the dominant species present in each site. Thus, for
Malawi and Uganda, only P. falciparum antigens are repre-
sented, whereas for Colombia and Amazonia only P. vivax
antigens are represented. The slopes generated by such analy-
ses for all ICEMR sites tested to date are provided in Table 2.
To better evaluate the relationship of overall seroreactivity
in each site with malaria prevalence, the cumulative antibody
reactivity to Pf antigens for sites that had predominantly
falciparum malaria (Figure 6, left panel) and to Pv antigens
for areas with primarily vivax malaria (Figure 6, right panel)
are shown. The strength and breadth of serological reactivity
to Pf showed an almost linear correlation between Pf prev-
alence, especially for the three sites in Malawi (Figure 6,
left panel). Tororo, Uganda, with the highest prevalence of
any of the sites tested, appeared to be an outlier since the
overall reactivity was not as high as predicted by the trend.
This suggests a complex relationship between exposure and
antibody responses. Under low-transmission conditions, a
malaria infection can result in lower although persistent anti-
body responses. Whereas under very high transmission condi-
tions, it is possible that humoral immunity may be dampened
by potent immunoregulatory mechanisms, for example, due to
TABLE 2
Relative antigen reactivity to Pf and/or Pv arrays across all the ICEMR sites
Country Location
Slope
(all antigens)
Slope
(Pf antigens)
Slope
(Pv antigens)
PNG East Sepik Province 2.629 2.429 2.544
Uganda Kanungu 2.476 2.764 1.594
Peru Santa Emilia 2.334 2.248 2.472
Malawi Chikwawa 2.080 2.300 1.770
Uganda Tororo 1.671 1.895 1.171
Solomon Islands Halavo, Tadolo 1.431 1.262 2.048
Uganda Jinja 1.202 1.351 0.792
Malawi Thyolo 1.103 1.130 1.147
Brazil Remansinho 0.935 0.784 1.410
Malawi Ndirande 0.849 0.900 0.778
Thailand Mae Salid Noi 0.837 0.833 0.823
Senegal Senegal 0.581 0.598 0.555
Colombia Tierralta 0.579 0.487 0.836
Colombia Tumaco 0.544 0.562 0.529
Zambia Choma District 0.532 0.545 0.525
Colombia Buenaventura 0.504 0.532 0.460
Peru Madre-de-Dios 0.473 0.380 0.649
Peru Iquitos 0.460 0.363 0.676
United States 0.397 0.322 0.651
ICEMR = International Centers of Excellence in Malaria Research; Pf = Plasmodium falciparum; Pv = Plasmodium vivax.
FIGURE 6. The relationship of parasite prevalence at a population level and the overall breadth and magnitude of serological reactivity as
measured by sum log2 fold increased over controls (FOC) for every Pf antigen on the array. The left panel is Pf antigens and sites with predomi-
nantly Pf transmission. The right panel shows reactivity to Pv antigens at International Centers of Excellence in Malaria Research (ICEMR)
sites with predominantly Pv. Prevalence is based on blood smear and/or rapid diagnostic test (RDT) (see review by Moss W. J., and others in
this volume) and may be an underestimate, notably in Thailand.12
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rapid consumption of antibodies and impairment of memory
in the setting of recurrent, high-density parasitemia.
The correlation between prevalence and Pv reactivity also
shows the same trend as Pf, although the relationship is
probably more complex (Figure 6, right panel). First, most sites
with predominant Pv infections also have some Pf transmis-
sion that can contribute significant serological cross-reactivity
between many Pv and Pf antigens (Figures 3 and 4). Also, a
majority of blood-stage Pv infections likely arise from relaps-
ing Pv parasites from hypnozoites. The relapsing patterns
can differ significantly between sites25 and may often present
as low-density infections that can be missed by routine sur-
veillance methods including molecular methods. Of note,
the Thailand site has documented a significant prevalence
of submicroscopic infections (~9% by polymerase chain
reaction [PCR]) accounting for its higher than expected
serological reactivity.
Biosignatures of NAI. Several studies are underway as
part of the ICEMR program to define biosignatures of NAI.
Three study designs are currently being used to identify indi-
viduals with clinical immunity to malaria. It is hypothe-
sized immune subjects will differentially recognize a subset
of malaria proteins that would represent a biosignature of
clinical immunity. The first and most powerful is the longi-
tudinal cohort study, where individuals are actively and pas-
sively followed at regular intervals (often every 2 weeks or
monthly) with the aim that most or all malaria infections and
illnesses are captured. Biosignatures of protection are mea-
sured in serum or plasma samples and are related to risk
of clinical malaria, accounting for varied exposure, over the
course of follow-up. Such studies are labor intensive and
require populations with sufficiently high transmission levels
such that enough clinical events are captured to have suffi-
cient statistical power. An example of this approach using the
microarray and correlates of immunity (non-ICEMR) was
recently published.26 Similar studies in the Uganda and south-
west Pacific ICEMRs are currently underway.
The second are serial cross-sectional studies in the same
population. Often the same individuals are observed repeat-
edly, but surveys are less frequent than cohort studies and
missing data on individuals is much more common than in
the cohort studies (there is no active follow-up of individuals).
With good passive surveillance, most symptomatic malaria
cases are captured. The dynamics of asymptomatic infections
are missed however. An example of such a study (also non-
ICEMR) showed that children with higher overall serological
reactivity to Pf antigens on the microarray were signifi-
cantly less likely to acquire symptomatic malaria compared
with those with lower overall serological responses during
the transmission season.13 Investigators are performing similar
analyses with focus on Pv in Remansinho, Brazil ICEMR.27
The third approach is a comparison of asymptomatic versus
symptomatic parasitemic individuals (i.e., a case–control study
design) in cross-sectional surveys. Persons with blood-stage
malaria infections (often detected by molecular methods such
as PCR) in the absence of clinical symptoms are considered
to be clinically immune compared with those with symptom-
atic malaria. Although this approach is the most tractable
study design, it has the weakness that an accurate malaria his-
tory may not be available, and putatively immune individuals
may have been recently ill with malaria. It is also possible that
these are just long-standing infections to which the individual
has developed some level of strain-specific immunity from
prolonged submicroscopic infection. Such studies are under-
way at a number of sites. An example of such an approach
was recently completed in Peru ICEMR.28 In this study, sera
from symptomatic (N = 24) by passive case detection and
asymptomatic (N = 14) P. falciparum malaria infections (blood
smear positive in the absence of any malaria referable symp-
toms in previous 2 weeks) in carefully age-matched (nested)
cohorts were probed on the Pf824 microarray to identify dif-
ferentially recognized antigens that may be associated with
protection. The number of prior malaria episodes was
similar between the two groups as well as the median age
(27 and 32 years for symptomatic versus asymptomatic,
respectively). Median parasite densities, however, were more
than log-fold higher in symptomatic individuals compared
with asymptomatic individuals, which may have contributed
to consumption of antibodies. On the basis of mean MFI,
52 antigens were found to be differently reactive between
samples from these two different patient groups (P value
≤ 0.05, corrected for false discovery Figure 7). Importantly,
the asymptomatic participants had overall higher antibody
reactivity. Of these differentially recognized antigens, 13 were
identified as conserved Plasmodium spp. proteins of unknown
function. PfMSP-1 (gene identification, PFI1475w), an estab-
lished vaccine candidate, showed the highest reactivity among
the differentially reactive antigens. Other vaccine candidates
found were EBA175 (MAL7P1.176) and liver-stage antigen 3
(LSA3, ID PFB0915w). Ring erythrocyte surface antigen
(PFA0110) was also differentially reactive; this protein has
been reported to be involved in modifying the biophysical
properties of infected erythrocytes and the effect seems to be
enhanced by increasing temperature to fever levels. Two heat
shock proteins, HSP40 (PFE0055ce4) andHSP70 (MAL7P1.228),
were differentially recognized. Several other differentially recog-
nized proteins are involved in interactions of infected red
blood cells (RBCs) with uninfected RBCs and endothelial
cells: ring-exported protein 1 (ID: PFI1735c), early transcribed
membrane proteins (E-TRAMPs) 4,5,10.1, and 14.1 (IDs:
PFD1120c, PFE1590w, PF10_0019, and PF14_0016).
It should be emphasized that the majority of antigens on
the array did not show any difference between the two groups
and some of these had the highest overall seroreactivity
that could be potential biosignatures of exposure. Examples
of highly seroreactive antigens in both groups are PfMSP10,
PfRh2, MSP1, and LSA3.
DISCUSSION
Much of the data presented in this article provide the basis
for more detailed studies to identify optimal antigens for bio-
signatures of transmission and NAI. In the following discus-
sion, we describe these preliminary findings in the broader
context of the present understanding and approaches to iden-
tify biosignatures of transmission and acquired immunity.
Biosignatures of transmission. Antibody responses to
Plasmodium have been used for decades to assess exposure
to infecting parasites and thus characterize transmission. To
date, the most standardized and widely validated method
for evaluating exposure via serology is the seroconversion rate
(SCR), which appears to be informative across a broad range
of transmission settings. Typically SCR is calculated from
age-specific seroprevalence, with seropositive individuals
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representing both presently infected and previously exposed
individuals depending on the kinetics of antibody responses to
the particular antigen.
Calculation of an SCR extends seroprevalence analysis
by calculating the rate at which individuals in a population
become seropositive. SCR is analogous to the force-of-infection
and is derived from the analysis of seroprevalence as func-
tion of age.29 A curve is fitted to observed age seroprevalence
data, most commonly using reverse catalytic models fit by
maximum likelihood.30 In these models, age of individuals
is assumed to be a proxy of time and individuals move
between seronegative and seropositive states on malaria
exposure and absence of reinfection. This assumption may
not be accurate in all populations where people may migrate
from malaria nonendemic to endemic areas such as the Brazilian
Amazon. SCR is defined as the rate at which seronegative indi-
viduals convert to seropositive and the converse (seropositive
individuals reverting to a seronegative state) is the serorever-
sion rate (SRR). SRR is related to antibody decay in the
absence of disease exposure and is related to a variety of factors
as described above. Other models that use a stacking process
to move between several levels of seropositivity and or antibody
data as a continuous variable have also been developed.31
Several studies have demonstrated the utility of SCR as
a malaria epidemiological measure, which can be collected
from a variety of survey types (community, school, and health
facility) and that shows good agreement with classic mea-
sures of malaria transmission intensity such as the entomo-
logical inoculation rate.30 Other studies have highlighted the
unique property of serology in its ability to estimate histori-
cal exposure levels and also to demonstrate reductions in
exposure to infection-associated interventions.32,33 A number
of ICEMR programs are using or are planning to use SCR to
estimate transmission. In Columbia, estimates of SCR using
responses to Pv circumsporozoite protein accurately strati-
fied risk between the three sites; in Uganda, estimates of
SCR using responses to Pf apical membrane antigen 1 also
accurately stratified risk between the three sites, in contrast
with parasite prevalence.34
One important question being addressed in the ICEMR
program is defining the optimal antigenic targets for evaluat-
ing exposure, including how these may vary in different epi-
demiologic settings, and when evaluated in different age
groups. This is important as the dynamics of antibody acqui-
sition and maintenance vary based on exposure intensity,
thus the degree to which some serologic markers are infor-
mative of exposure will likely vary in these contexts. More-
over, the different kinetic properties of antigens should allow
a more refined characterization of the time elapsed since
exposure occurred, for example, using antigens with short
half-lives to reflect more recent exposure.7
In this study, we developed a targeted protein microarray
to examine antibody response to both Pv and Pf antigens
with ultimate aim to identify a set of novel serological assays
as biosignatures of transmission and NAI using antibodies
targeting a suite of particular proteins. The serological assays
that identify transmission versus those for acquired immunity
may differ, although there may be some overlap.
Overall, the array identified antigens that were gener-
ally more reactive in subjects residing in high- versus low-
transmission conditions, however this relationship was
imprecise and some individuals living in high-transmission
areas had lower overall responses compared with those
living in lower transmission areas. Since malaria transmis-
sion can be highly heterogenous and vary greatly with age,
more precise analyses are currently underway to better
FIGURE 7. Differential expression of antibodies to 52 malaria antigens in asymptomatic (blue bars) and symptomatic subjects (red bars). Shown
are the log-transformed MFI values and the Benjamini–Hochberg corrected P values < 0.05.
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control for these variables and to better select the more
informative antigens.
The issue of cross-reactivity between antigens especially in
areas where both Pf and Pv are endemic is important. This
may not be of great significance where one species is much
more prevalent compared with the others, for example, Pf in
sub-Saharan Africa and Pv in many areas of Latin America;
however, there are many areas where both are co-endemic.
We show some initial approaches to identification non-
cross-reactive antigens using serum samples from areas
that are only Pf or Pv endemic from careful studies in the
ICEMR. As might be expected, non-orthologous gene prod-
ucts are most likely to be non-cross-reactive between Pf and
Pv, although some orthologous genes are cross-reactive.
Studies are currently underway to identify the most infor-
mative species-specific antigens.
Another important question being addressed is evaluating
whether alternative methods for estimating transmission
from serology can provide more information from fewer sub-
jects, and/or information not easily obtainable from current
methods, in particular, quantifying recent changes in expo-
sure or defining heterogeneity in exposure at a more granular
level. Whether the same antigens are associated with clinical
immunity as determined by a similar study design or cohort
studies in other malaria-endemic settings are a goal of ongo-
ing ICEMR studies.
A separate protein microarray study, targeted specifically
at identifying serologic biomarkers of exposure, is testing
the hypothesis that individual-level estimates of exposure
can be obtained from a limited number of properly chosen
antibody responses. This study is leveraging detailed cohort
studies from the east African ICEMR to obtain individual-
level exposure data, and using flexible, data adaptive models
to identify the most informative biosignatures. Data from
these ongoing studies suggest that antibody responses to three
properly chosen antigens can provide detailed information
regarding recent exposure in individuals and can be aggre-
gated to provide accurate estimates of population-level expo-
sure within and between communities. Protein production of
these promising antigens is underway, with plans to evaluate
the kinetics of these responses and their ability to inform
exposure across multiple epidemiologic settings, taking advan-
tage of the rich epidemiologic data and sample bank being
collected as part of the ICEMR program. In addition, sepa-
rate studies to perform novel candidate discovery across indi-
viduals from distinct groups of age and exposure settings are
planned. Other studies are currently underway to examine
biosignatures of exposure to Pf in Zambia and Zimbabwe
(South Africa ICEMR), biosignatures of Pv in Peru, Brazil
(Amazonia ICEMR), in PNG and Solomon Islands (south
west Pacific ICEMR), and in Thailand and Columbia where
transmission levels are very low.
Biosignatures of NAI. NAI is now recognized as a major
determinant of the incidence and prevalence of malaria
infection and disease in endemic areas.35–38 Generally, NAI
influences not only the age-specific incidence and preva-
lence of Pf and Pv infection, but also the pathological pro-
cesses that underlie the clinical manifestations of infection.
Improved understanding of the development and mainte-
nance of NAI and the ability to cope with the severe mani-
festations of malaria are now particularly important, since
effective public health interventions that reduce transmis-
sion are being deployed. Knowledge of the underlying mech-
anisms of NAI will also be invaluable in the design and
evaluation of additional tools that prevent and treat malaria-
related illness, most especially in constructing vaccines that
ultimately eliminate the disease. Moreover, the identifica-
tion of a biosignature of NAI can help determine whether
populations are at a high risk of disease with malaria infec-
tion and whether this risk changes as interventions success-
fully reduce transmission.
Anti-parasite and anti-disease immunity are often corre-
lated, but develop at different rates and likely differ at least
in part in their underlying mechanisms of action. Indeed,
an ongoing analysis of cohort data from the Ugandan and
southwest Pacific ICEMRs aims to quantify the relationships
between each of these types of immunity with age and expo-
sure and their relationship to each other. In general, low
parasitemia levels in an immunologically naive individual will
cause disease so the presence of malaria infection in other-
wise clinically asymptomatic individuals reflects immunity
to disease, suggesting malaria-exposed individuals develop
a type of “tolerance” to malaria infection. What comprises
this tolerance remains poorly understood, but likely com-
prises several components. First is acquisition of immunity
to components of the malaria parasites that trigger innate
inflammatory responses, for example, antibodies that may
interfere with pro-inflammatory glycoprotein to Toll-like
receptors.39,40 Second is development of immunoregulatory
responses by the host that attenuate the host response to
parasite products such as anti-inflammatory cytokines such
as interleukin-10, expansion of malaria-specific regulatory
T cells,41–43 and/or B- and T-cell exhaustion.44 Ongoing studies
in the Uganda and southwest Pacific ICEMRs are examining
such immunoregulatory responses in detail.
The mechanisms that govern NAI remain elusive, although
our knowledge has expanded greatly over the past several
decades. Studies performed over 50 years ago showed that
transfer of IgG from clinically immune adults to children
symptomatic with malaria markedly attenuated their infec-
tion and disease, demonstrating the critical role of antibodies
in blood-stage immunity.45 To which parasite antigens these
protective antibodies bind and how they contribute to clear-
ance of blood-stage parasites has been a focus of intense
study. Although absolute in vitro correlates of protection to
malaria are unknown, consensus has emerged that there are
specific biosignatures of immunity. These include elevated
levels of serum antibodies directed at merozoite antigens
(particularly invasion ligands) and/or variant surface anti-
gen on infected erythrocytes.46–48 These responses repre-
sent associations rather than causal relations of protective
immunity, but they are valuable if they can predict the level
of NAI in populations before and after the implementa-
tion of malaria control measures. A likely scenario is that
once antibody levels that target multiple merozoite antigens
involved in erythrocytes invasion and/or surface proteins
expressed on the malaria-infected erythrocytes reach a criti-
cal threshold, clinical immunity develops (Figure 8). The
decline of these responses below this critical threshold may
predict susceptibility to infection.
The overall goal of the trans-ICEMR studies is to identify
a constellation of malaria antigen-specific antibodies whose
levels are consistently associated with NAI using different
epidemiological approaches. However, it may be that the
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correlates of exposure vary in different epidemiologic set-
tings or age groups. Importantly, as the frequency of clinical
malaria diminishes resulting from interventions that reduce
malaria transmission, the development of NAI will also
diminish or shift to older individuals. As a consequence ideal
biosignatures may also change in accordance with epidemio-
logical studies monitoring changes in the incidence and/or
prevalence of clinical malaria. The aim is to identify sero-
logical tests that can identify individuals lacking adequate
NAI resulting in an increased risk of clinical malaria. Such
monitoring can alert the public health system when NAI in
the population declines below a critical level, leaving the
population prone to epidemics with potentially high mor-
bidity. Initial results from the southwest Pacific ICEMR sug-
gest a critical threshold can be defined based on seroreactivity
to relatively small group of antigens.49
Additional immunological markers associated with NAI.
Because of its relative simplicity, the primary focus of ICEMR
efforts has been on serological biosignatures of transmis-
sion and immunity; however, effector mechanisms of immu-
nity are complex. For example, the ability of antibodies to
opsonize malaria-infected erythrocytes or merozoites might
better correlate with clinical immunity.50 Similarly, the ability
of antibodies to fix complement and/or block merozoite inva-
sion or schizont release from erythrocytes may identify a clini-
cally important subset of antibodies. Measuring host cellular
responses may also be important.51 It is likely one or more
of these pathways is involved in NAI and may vary with
time and parasite strain in the same individual, which has
made it difficult to consistently identify robust correlates
of immunity.
CONCLUSIONS
The knowledge obtained from ICEMR-related studies will
begin to address critical gaps in our understanding of natu-
rally acquired humoral immune response against Pf and Pv
to inform malaria vaccine development and identify potential
new biosignatures associated with exposure and protection
worldwide. These data will improve and broaden our under-
standing of how NAI develops around the world as a func-
tion of age and exposure and will be useful to monitor
eradication and control measures underway in the different
ICEMRs. The project may also contribute to the discovery
of vaccine antigen candidates to boost NAI to asexual and
sexual stage parasites.
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